Prostatype Genomics AB (OSTO:PROGEN) Net Change in Cash : kr2.88 Mil (TTM As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Prostatype Genomics AB's Net Change in Cash for the three months ended in Jun. 2023 was kr9.52 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was kr2.88 Mil.

Prostatype Genomics AB Net Change in Cash Historical Data

The historical data trend for Prostatype Genomics AB's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Net Change in Cash Chart

Prostatype Genomics AB Annual Data

Trend

Jun18

Jun19

Dec21

Dec22

Dec23

Net Change in Cash

-2.27

-5.52

4.47

-8.84

-8.81

Prostatype Genomics AB Quarterly Data
	Jun18	Jun19	Mar20	Jun20	Sep20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Net Change in Cash	Get a 7-Day Free Trial											10.63	-7.95	-9.32	9.52	-

Prostatype Genomics AB Net Change in Cash Calculation

Prostatype Genomics AB's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-29.138	+	-8.566	+	28.911	+	-0.013
	=	-8.81

Prostatype Genomics AB's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -11.061 + 0.005 + 20.579 + 0

= 9.52

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Prostatype Genomics AB's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Prostatype Genomics AB (OSTO:PROGEN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Net Change in Cash

Comparable Companies

XSAT:SPERM OSTO:IMMNOV XSAT:GEAN XSAT:ALPH XSAT:CALMA B NGM:ATANA OSTO:AROC TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX WAT

Traded in Other Exchanges

PGO:Germany

Address

Gustaf III:s Boulevard 34, Solna, SWE, 169 73

Website

https://www.prostatypegenomics.com

Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB (OSTO:PROGEN) Headlines

No Headlines